Key points are not available for this paper at this time.
In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.
Kaufman et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: